Cargando…

Design and development of a new lentiviral based anti-HIV therapeutic vaccine

Detalles Bibliográficos
Autores principales:	Rodriguez, M, Sarry, E, Bejanariu, A, Casaban, L, Abdalla, S, Sabbah-Petrover, E, Bauche, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442022/ http://dx.doi.org/10.1186/1742-4690-9-S2-P350

Ejemplares similares

Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical studies and phaseI/II clinical trial preliminary results
por: Bauche, Cécile, et al.
Publicado: (2014)

P17-20. Lentiviral vector-based vaccine against SIV infection and simian AIDS
por: Beignon, A, et al.
Publicado: (2009)

Dendritic cell nediated inhibition of lentiviral infection
por: Drake, A, et al.
Publicado: (2012)

P03-01. The relationship of envelope evolution to lentiviral persistence and vaccine efficacy
por: Craigo, JK, et al.
Publicado: (2009)

Simian immunodeficiency virus-Vpx as an adjuvant for integrase defective lentiviral vector-based vaccines
por: Blasi, M, et al.
Publicado: (2012)

Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
por: Albershardt, Tina C, et al.
Publicado: (2015)

P12-15. Replication enhancement of an alphaviral-lentiviral replicating chimeric particle (RCP) vaccine
por: Young, K, et al.
Publicado: (2009)

P19-40. Different forms of a lentiviral glycoprotein presented by bivalent measles virus vaccines
por: Heidmeier, S, et al.
Publicado: (2009)

Identifying features of the lentiviral genome crucial for the establishment of latency
por: Ziglio, Serena, et al.
Publicado: (2013)

A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity
por: Garrett, Tracy E, et al.
Publicado: (2015)

P17-16. Anti-Langerin-HIV Gag p24 fusion protein targeting Langerhans cells as a new anti-HIV vaccine strategy
por: Culina, S, et al.
Publicado: (2009)

New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants
por: Penezina, O, et al.
Publicado: (2012)

From HIV protein sequences to viral fitness landscapes: a new paradigm for in silico vaccine design
por: Ferguson, AL, et al.
Publicado: (2012)

In-silico designing of acyclic nucleoside phosphonates and their anti-HIV potential
por: Yadav, Dipti, et al.
Publicado: (2012)

Pilot trial of oral therapeutic HIV vaccine, V-1 Immunitor, on HIV and HIV/HCV patients in Russia
por: Bourinbaiar, Aldar, et al.
Publicado: (2010)

Increased PD-1 expression in cynomolgus and rhesus macaques during lentiviral infection
por: Hokey, David A, et al.
Publicado: (2006)

P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success
por: De Groot, AS, et al.
Publicado: (2009)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

The recognition of HIV-1 consensus group M Gag and Nef peptide reagents in mono- and multi-clade epidemics: implications for HIV vaccine design
por: Zembe, L, et al.
Publicado: (2012)

Novel insights from structural analysis of lentiviral and gammaretroviral reverse transcriptases in complex with RNA/DNA hybrids
por: Le Grice, Stuart, et al.
Publicado: (2013)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

Interleukin-1 receptor antagonist lentiviral gene transfer to the murine knee joint ameliorates collagen-induced arthritis
por: van de Loo, FAJ, et al.
Publicado: (2005)

P19-28. The V3 region of HIV-1: from NMR to vaccine design
por: Moseri, A, et al.
Publicado: (2009)

Therapeutics designed to neutralize soluble HIV tat protein could preserve IL-7 signaling and CD8 T-cell function in HIV+ patients
por: Faller, EM, et al.
Publicado: (2010)

P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients
por: Karita, E, et al.
Publicado: (2009)

P19-45. Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens
por: Cobb, AJ, et al.
Publicado: (2009)

Mutational analysis of H5N1 hemagglutinins: identification of molecular determinants for efficient packaging into pseudotyped lentiviral particles
por: Tang, DJ, et al.
Publicado: (2011)

P05-01. Generation of a HI-viral packaging cell line as scaffolding for a lentiviral display system
por: Schilling, K, et al.
Publicado: (2009)

Anti-HIV and immune modulating activities of IND02
por: Biedma, ME, et al.
Publicado: (2012)

P18-08. Characterization of CD34+ derived dendritic cells generated in vitro and transfected with HIV gene as potential therapeutic vaccine in macaque
por: Romain, G, et al.
Publicado: (2009)

A "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells
por: Albershardt, Tina C, et al.
Publicado: (2014)

Antigenic mimicry of mammalian oligomannose by a naturally occurring bacterial oligosaccharide and its implications for HIV vaccine design
por: De Castro, C, et al.
Publicado: (2012)

Breadth or conservation score (CS): which is more important for HIV-1 T cell based vaccine immunogen design?
por: Kunwar, P, et al.
Publicado: (2012)

Nutricional value of two protein hydolysates selected for the design of a new therapeutic infant formula
por: Matencio, Esther, et al.
Publicado: (2011)

Neutralizing anti-HIV antibodies develop in a humanized mouse model of HIV-1 infection
por: Seung, E, et al.
Publicado: (2012)

P18-10. Ability of HIV antigens-pulsed monocyte-derived dendritic cells to induce HIV-specific T cell response: potential use in therapeutic vaccine
por: Silveira, GG, et al.
Publicado: (2009)

P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
por: Wild, J, et al.
Publicado: (2009)

Nef variants from non-pathogenic lentiviral strains inhibit iron uptake through an AP2-dependent inhibition of transferrin endocytosis
por: Koppensteiner, Herwig, et al.
Publicado: (2013)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lipg7veh1b8dula4npshmg097i